McCoin CS, Knotts TA, Ono-Moore KD, Oort PJ, Adams SH
Using lower doses with comprehensive support actually reduces risk
Individuals with a history of medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2, or those who've experienced pancreatitis or severe gastrointestinal diseases should discuss alternatives with their provider
The good news is that oral semaglutide holds its own
Plateaus on GLP-1 therapy happen for a few predictable reasons: your dose needs to go up, your body has adapted to your current medication, or there's a metabolic factor (thyroid, insulin resistance, cortisol) that bloodwork would reveal and guesswork won't